Transparent Public Pricing for Biosimilars: pCPA Releases First Principles for SEBs

Guest Blog By Arvind Mani Director of Market Access and Policy Research PDCI Market Access The pan-Canadian Pharmaceutical Alliance (pCPA) recently issued a communiqué outlining their initial perspective on subsequent entry biologics (SEBs) and innovative/reference biologics as it aims to establish a SEB policy framework.  Key Takeaways It appears that the pCPA’s first principles for SEBs are targeted at ensuring that manufacturers of both SEB and

Watch: Jackie Manthorne Featured in Amgen Canada’s Video on Biosimilars!

Amgen Canada is proud to share an online video series they have developed on biosimilars. The videos were released today in the digital version of The Globe & Mail. For the past several months, Amgen has worked with The Globe & Mail to create these online videos that cover the key issues on biosimilars. Participants included Amgen Canada’s Karen Burke, who provided perspective on biosimilars